Your browser doesn't support javascript.
loading
Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management.
Gudenkauf, Lisa M; Gray, Struan; Gonzalez, Brian D; Sachdeva, Ashwin; Autio, Karen.
Afiliación
  • Gudenkauf LM; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.
  • Gray S; Salford Royal and The Christie NHS Foundation Trusts, Manchester, United Kingdom.
  • Gonzalez BD; Genito-urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
  • Sachdeva A; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.
  • Autio K; Genito-urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Am Soc Clin Oncol Educ Book ; 44(3): e433126, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38788186
ABSTRACT
Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be addressed. This review aims to highlight opportunities to mitigate AEs of ADT and explore alternatives in PCa management. Specifically, we discuss behavioral and pharmacologic strategies for mitigating ADT AEs as well as ADT-sparing approaches for hormone-sensitive and castration-resistant PCa. Equipped with effective mitigation strategies and possible alternatives, clinicians and researchers can optimize health-related quality of life for patients currently receiving ADT for PCa and consider treatments that spare patients from AEs of ADT.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Próstata / Calidad de Vida / Antagonistas de Andrógenos Límite: Humans / Male Idioma: En Revista: Am Soc Clin Oncol Educ Book Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias de la Próstata / Calidad de Vida / Antagonistas de Andrógenos Límite: Humans / Male Idioma: En Revista: Am Soc Clin Oncol Educ Book Año: 2024 Tipo del documento: Article